Clinical trial of YPS345, a class 1 innovative drug, was approved by the State Drug Administration

Today, chinaPharmaceutical(http://issued a notice that its wholly-owned
subsidiary(http://Tianfang Pharmaceutical Co., Ltdreceived a notice of acceptance of the clinicaltest(http://) of the 1 class of chemical sin sinnew drugs(http://YPS345 approved by the StatePharmaceutical(http://Supervision Authority the deadline, Tianfang Limited has invested a total of about 19.84 million yuan in research and development projects in this category of drugs the YPS345 YPS345 project is a class 1 innovative chemical developed by Tianfang Pharmaceuticals and the Institute of Biophysics of the Chinese Academy of Sciences, intended to be used in the treatment of pneumonia and pulmonary fibrosis caused by chest radiation therapy in tumor patients, and there is no of the same product (http:// in the market Tianfang Pharmaceuticals in the yPS345 non-clinical trial research stage, the effectiveness and safety results show that as a drug to prevent and treat radioactive inflammation (http:// , it has significant remission to animal models of chemotherapy-induced pulmonary fibrosis, and good safety at the same time, according to the completed mechanism of action research found that YPS345 can be inhibited by the associated inflammatory factor intracellular transport and secretion of the regulatory mechanism, so as to prevent radiation-induced lung damage